Hyaluronidase Induction of a WW Domain-containing Oxidoreductase That Enhances Tumor Necrosis Factor Cytotoxicity*

To determine how hyaluronidase increases certain cancer cell sensitivity to tumor necrosis factor (TNF) cytotoxicity, we report here the isolation and characterization of a hyaluronidase-induced murine WW domain-containing oxidoreductase (WOX1). WOX1 is composed of two N-terminal WW domains, a nuclear localization sequence, and a C-terminal alcohol dehydrogenase (ADH) domain. WOX1 is mainly located in the mitochondria, and the mitochondrial targeting sequence was mapped within the ADH domain. Induction of mitochondrial permeability transition by TNF, staurosporine, and atractyloside resulted in WOX1 release from mitochondria and subsequent nuclear translocation. TNF-mediated WOX1 nuclear translocation occurred shortly after that of nuclear factor-κB nuclear translocation, whereas both were independent events. WOX1 enhanced TNF cytotoxicity in L929 cells via its WW and ADH domains as determined using stable cell transfectants. In parallel with this observation, WOX1 also enhanced TRADD (TNFreceptor-associated deathdomain protein)-mediated cell death in transient expression experiments. Antisense expression of WOX1 raised TNF resistance in L929 cells. Enhancement of TNF cytotoxicity by WOX1 is due, in part, to its significant down-regulation of the apoptosis inhibitors Bcl-2 and Bcl-xL (>85%), but up-regulation of pro-apoptotic p53 (∼200%) by the ADH domain. When overexpressed, the ADH domain mediated apoptosis, probably due to modulation of expression of these proteins. The WW domains failed to modulate the expression of these proteins, but sensitized COS-7 cells to TNF killing and mediated apoptosis in various cancer cells independently of caspases. Transient cotransfection of cells with both p53 and WOX1 induced apoptosis in a synergistic manner. WOX1 colocalizes with p53 in the cytosol and binds to the proline-rich region of p53 via its WW domains. Blocking of WOX1 expression by antisense mRNA abolished p53 apoptosis. Thus, WOX1 is a mitochondrial apoptogenic protein and an essential partner of p53 in cell death.

[1]  Xinbin Chen,et al.  Definition of the p53 Functional Domains Necessary for Inducing Apoptosis* , 2000, The Journal of Biological Chemistry.

[2]  D. K. Kuharsky,et al.  Bid-induced Cytochrome c Release Is Mediated by a Pathway Independent of Mitochondrial Permeability Transition Pore and Bax* , 2000, The Journal of Biological Chemistry.

[3]  V. Mootha,et al.  tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. , 2000, Genes & development.

[4]  R. Richards,et al.  Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. , 2000, Human molecular genetics.

[5]  T. Graf,et al.  MafB is an inducer of monocytic differentiation , 2000, The EMBO journal.

[6]  A. Bednarek,et al.  WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. , 2000, Cancer research.

[7]  J. Sgouros,et al.  A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D. , 2000, Cancer research.

[8]  R. Shalaby,et al.  Alternatively Spliced Products CC3 and TC3 Have Opposing Effects on Apoptosis , 2000, Molecular and Cellular Biology.

[9]  D. Green,et al.  Caspases Induce Cytochrome c Release from Mitochondria by Activating Cytosolic Factors* , 1999, The Journal of Biological Chemistry.

[10]  Masashi Narita,et al.  Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC , 1999, Nature.

[11]  Lin-Feng Chen,et al.  A WW domain‐containing Yes‐associated protein (YAP) is a novel transcriptional co‐activator , 1999, The EMBO journal.

[12]  A. Komuro,et al.  Npw38, a novel nuclear protein possessing a WW domain capable of activating basal transcription. , 1999, Nucleic acids research.

[13]  Ruedi Aebersold,et al.  Molecular characterization of mitochondrial apoptosis-inducing factor , 1999, Nature.

[14]  Y. Zhao,et al.  Cloning and characterization of a novel transforming growth factor-beta1-induced TIAF1 protein that inhibits tumor necrosis factor cytotoxicity. , 1998, Biochemical and biophysical research communications.

[15]  N. Chang.  Transforming growth factor-beta protection of cancer cells against tumor necrosis factor cytotoxicity is counteracted by hyaluronidase (review). , 1998, International journal of molecular medicine.

[16]  C. Méndez-Vidal,et al.  Reversal of P-glycoprotein-mediated multidrug resistance in vitro by AV200, a new ardeemin derivative. , 1998, Cancer letters.

[17]  M. Soloway,et al.  Secretion of bladder tumor-derived hyaluronidase activity by invasive bladder tumor cells. , 1998, Cancer letters.

[18]  G. Baumgartner,et al.  The impact of extracellular matrix on the chemoresistance of solid tumors--experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. , 1998, Cancer letters.

[19]  P. Leder,et al.  WW domain-mediated interactions reveal a spliceosome-associated protein that binds a third class of proline-rich motif: the proline glycine and methionine-rich motif. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  N. Chang,et al.  Cloning and characterization of a transforming growth factor beta 1-induced anti-apoptotic adhesion protein TIF2. , 1998, Biochemical and biophysical research communications.

[21]  Dean P. Jones,et al.  Mitochondrial control of apoptosis: the role of cytochrome c. , 1998, Biochimica et biophysica acta.

[22]  J Schultz,et al.  SMART, a simple modular architecture research tool: identification of signaling domains. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  W. Fiers,et al.  Inhibition of Caspases Increases the Sensitivity of L929 Cells to Necrosis Mediated by Tumor Necrosis Factor , 1998, The Journal of experimental medicine.

[24]  S. Nattel,et al.  Characterization of a transient outward K+ current with inward rectification in canine ventricular myocytes. , 1998, American journal of physiology. Cell physiology.

[25]  D. Brenner,et al.  NFkappaB prevents apoptosis and liver dysfunction during liver regeneration. , 1998, The Journal of clinical investigation.

[26]  A. Le Saux,et al.  The mitochondrial ADP/ATP carrier: structural, physiological and pathological aspects. , 1998, Biochimie.

[27]  S. Yamagata,et al.  Difference of hyaluronidase produced by human tumor cell lines with hyaluronidase present in human serum as revealed by zymography. , 1997, Biochemical and biophysical research communications.

[28]  B. Dörken,et al.  Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. , 1997, The Journal of clinical investigation.

[29]  C. Y. Wang,et al.  Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. , 1997, Science.

[30]  N. Chang.  Hyaluronidase enhancement of TNF-mediated cell death is reversed by TGF-beta 1. , 1997, The American journal of physiology.

[31]  C. Chauzy,et al.  Increased hyaluronidase levels in breast tumor metastases , 1997, International journal of cancer.

[32]  G. Natoli,et al.  Tumor Necrosis Factor (TNF) Receptor 1 Signaling Downstream of TNF Receptor-associated Factor 2 , 1997, The Journal of Biological Chemistry.

[33]  K. Smith,et al.  Hyaluronidase enhances the therapeutic effect of vinblastine in intralesional treatment of Kaposi's sarcoma. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). , 1997, Journal of the American Academy of Dermatology.

[34]  G. Natoli,et al.  Activation of SAPK/JNK by TNF Receptor 1 Through a Noncytotoxic TRAF2-Dependent Pathway , 1997, Science.

[35]  David Baltimore,et al.  An Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death , 1996, Science.

[36]  Marty W. Mayo,et al.  TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB , 1996, Science.

[37]  Michael Karin,et al.  Dissection of TNF Receptor 1 Effector Functions: JNK Activation Is Not Linked to Apoptosis While NF-κB Activation Prevents Cell Death , 1996, Cell.

[38]  R. Kerbel,et al.  Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. , 1996, Journal of the National Cancer Institute.

[39]  J. Willson,et al.  Expression of hyaluronidase by tumor cells induces angiogenesis in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. Mann,et al.  Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart , 1996 .

[41]  N. Block,et al.  Association of elevated levels of hyaluronidase, a matrix-degrading enzyme, with prostate cancer progression. , 1996, Cancer research.

[42]  D. Goeddel,et al.  The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation , 1995, Cell.

[43]  N. Chang.  Transforming Growth Factor-β1 Induction of Novel Extracellular Matrix Proteins That Trigger Resistance to Tumor Necrosis Factor Cytotoxicity in Murine L929 Fibroblasts (*) , 1995, The Journal of Biological Chemistry.

[44]  P. Bork,et al.  The WW domain: a signalling site in dystrophin? , 1994, Trends in biochemical sciences.

[45]  E. Maeyer,et al.  The growth rate of two transplantable murine tumors, 3LL lung carcinoma and B16F10 melanoma, is influenced by Hyal-1, a locus determining hyaluronidase levels and polymorphism. , 1992 .

[46]  Peer Bork,et al.  SMART: a web-based tool for the study of genetically mobile domains , 2000, Nucleic Acids Res..

[47]  T. Yamagata,et al.  Hyaluronidase activity in gynaecological cancer tissues with different metastatic forms. , 1997, British Journal of Cancer.

[48]  F. J. Geske,et al.  Use of the yeast two-hybrid system for identifying the cascade of protein interactions resulting in apoptotic cell death. , 1995, Methods in cell biology.